Back to Results

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Ross Camidge,  MD, PhD

Ross Camidge, MD, PhD

Study ID

Protocol Number: 18-1728

More information available at ClinicalTrials.gov: NCT03539536

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers